Mild Hypertension and Cardiovascular Risks
Authors: James F. Burris
Journal: Annals of Internal Medicine (1990)

Letters and Corrections1 June 1990Mild Hypertension and Cardiovascular RisksJames F. Burris, MDJames F. Burris, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-112-11-879_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor:It is very unfortunate that the TAIM (Trial of Antihypertensive Interventions and Management) study lasted only 6 months (1). It has been well known for some time that thiazide diuretics initially increase both total and low-density lipoprotein (LDL) cholesterol. The lipid changes probably peak at 6 to 9 months, and cholesterol declines to or below baseline thereafter (2). Such a relatively transient increase in cholesterol would not be expected to have any long-term effect on coronary risk. The TAIM study thus assessed chlorthalidone at the worst possible time for evaluating the long-term effect of thiazides on cardiovascular...References1. ObermanWassertheil-SmollerLangford ASH. Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Ann Intern Med. 1990;112:89-95. LinkGoogle Scholar2. Freis E. The cardiovascular risks of thiazide diuretics. Clin Pharmacol Ther. 1986;39:239-44. CrossrefMedlineGoogle Scholar3. CutlerMacMahonFurberg JSC. Controlled clinical trials of drug treatment for hypertension—a review. Hypertension. 1989; 13(Suppl I):I36-44. CrossrefMedlineGoogle Scholar4. FurbergCutler CJ. Diuretic agents versus beta-blockers—comparison of effects on mortality, stroke, and coronary events. Hypertension. 1989;13(Suppl I):I57-61. CrossrefMedlineGoogle Scholar1. ObermanWassertheil-SmollerLangford ASH. Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Ann Intern Med. 1990;112:89-95. LinkGoogle Scholar2. The 1988 Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Bethesda, Maryland: U.S. Department of Health and Human Services: 1988. NIH publication no. 88-1088. Google Scholar3. JohnsonDanylchuk BM. The relevance of plasma lipid changes with cardiovascular drug therapy. Med Clin North Am. 1989;73:449-73. CrossrefMedlineGoogle Scholar4. Ames R. Effects of diuretic drugs on the lipid profile. Drugs. 1988;36:33-40. CrossrefMedlineGoogle Scholar5. . Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1985;55:1-15. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: James F. Burris, MDAffiliations: Georgetown University Medical Center Washington, D.C. 20007 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1990Volume 112, Issue 11Page: 879-879KeywordsCholesterolDiureticsHypertensionLipidsLow density lipoprotein ePublished: 1 December 2008 Issue Published: 1 June 1990 PDF downloadLoading ...